Novartis’ $12B Biotech Buyout Shakes Up Avidity Biosciences (RNA) – Is the Rare-Disease Stock Set to Soar?
Bottom Line: Avidity Biosciences’ stock is set to explode higher on Novartis’s $12 billion buyout, capping off a dramatic run fueled by breakthrough science and takeover buzz. The high-premium deal underscores the